Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – When a thoracic aortic aneurysm ruptures, expedient endovascular repair in selected patients can save lives, an international group reports. They point out in…
NEW YORK (Reuters Health) – Azithromycin is not only an effective treatment for bronchiolitis obliterans syndrome (BOS) that occurs in many lung transplant patients, it can also prevent…
NEW YORK (Reuters Health) – The notable accumulation of visceral fat that occurs in some patients with HIV who are on antiretroviral drugs can be reduced substantially by…
NEW YORK (Reuters Health) – While some patients with acute coronary syndrome (ACS) and elevate natriuretic peptide levels can benefit from treatment with various suppressors of the renin-angiotensin-aldosterone…
NEW YORK (Reuters Health) – What appears to be a blue nevus might be a cutaneous melanoma metastasis. High resolution ultrasonography can aid dermatologists in making the differential…
NEW YORK (Reuters Health) – The adverse effects of conventional amphotericin B for treating acute cryptococcal meningitis in AIDS patients can be reduced significantly by using the liposomal…
NEW YORK (Reuters Health) – Radiographic progression of rheumatoid arthritis is reduced to comparable degrees by DMARDs (disease modifying anti-rheumatic drugs), glucocorticoids, biologics and combination treatments, a Danish…
NEW YORK (Reuters Health) – Few pediatric patients with complex febrile seizures have acute bacterial meningitis if other signs and symptoms are absent, clinicians at Children’s Hospital Boston,…
NEW YORK (Reuters Health) – A modified procedure intended to improve on Nissen fundoplication for gastroesophageal reflux disease has been shown in an Australian study to actually have…
NEW YORK (Reuters Health) – Patients with non-small-cell lung cancer harboring susceptibility mutations in the epidermal growth factor receptor (EGFR) did better with gefitinib given as first-line therapy…
